Study S003354

A Phase 1, Double-Blind, Parallel-arm, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection Administered Subcutaneously in Non-diabetic Overweight or Obese Adult Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06714955
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 30
Start: 2024-10-21
Primary completion: 2025-01-21
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Non-diabetic Overweight or Obese
Interventions: DRUG:Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.; DRUG:Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.; DRUG:Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Results posted: FALSE

Registered primary outcomes

Number of treatment adverse events [10 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.